Management of the stroke patient with patent foramen ovale: New insights and persistent questions in the wake of recent randomized trials

Current Atherosclerosis Reports

Volumn 15, Issue 7, 2013, Pages

  Peña, Jessica M ^a   Kizer, Jorge R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cryptogenic stroke; Patent foramen ovale; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE; WARFARIN;

ARTICLE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; HEART ANEURYSM; HEART ATRIUM FIBRILLATION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; NEUROPROTECTION; OUTCOME ASSESSMENT; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; PERCUTANEOUS CLOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SEPTAL OCCLUDER; STROKE PATIENT; THORACOTOMY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; BRAIN ISCHEMIA; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME; COMPLICATION; FORAMEN OVALE, PATENT; STROKE;

BRAIN ISCHEMIA; EMBOLISM, PARADOXICAL; FORAMEN OVALE, PATENT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SEPTAL OCCLUDER DEVICE; STROKE; TREATMENT OUTCOME;

EID: 84878136895     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0338-4     Document Type: Article

References (41)

1. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41. (Pubitemid 23014379)
2. Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e601S-36S.
3. Leys D, Bandu L, Hénon H, Lucas C, Mounier-Vehier F, Rondepierre P, et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology. 2002;59(1):26-33. (Pubitemid 34742790)
4. Johnson BI. Paradoxical Embolism. J Clin Pathol. 1951;4(3):316-32.
5. Conheim J. Thrombose und Embolie: Vorlesungen über allgemeine Pathologie. Berlin: Hirschwald; 1877.
6. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17-20. (Pubitemid 14175830)
7. Kizer JR, Devereux RB. Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med. 2005;353(22):2361-72. (Pubitemid 41713748)
8. Eggebrecht H, Naber CK, Plato C, Erbel R, Bartel T. Analysis of fossa ovalis membrane velocities by transesophageal Doppler tissue echocardiography: a novel approach to functional assessment of patent foramen ovale. J Am Soc Echocardiogr. 2004;17(11):1161-6. (Pubitemid 39402973)
9. Marriott K, Manins V, Forshaw A, Wright J, Pascoe R. Detection of right-to-left atrial communication using agitated saline contrast imaging: experience with 1162 patients and recommendations for echocardiography. J Am Soc Echocardiogr. 2013;26(1):96-102.
10. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318(18):1148-52.
11. Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Stroke. 2002;33(3):706-11. (Pubitemid 34203994)
12. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357(22):2262-8. (Pubitemid 350190756)
13. Pezzini A, Grassi M, Lodigiani C, Patella R, Gandolfo C, Zini A, et al. Interaction between proatherosclerotic factors and right-to-left shunt on the risk of cryptogenic stroke: the Italian Project on Stroke in Young Adults. Heart. 2012;98(6):485-9.
14. Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol. 2007;49(7):797-802. (Pubitemid 46240713)
15. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47(2):440-5. (Pubitemid 43063268)
16. Jauss M, Wessels T, Trittmacher S, Allendörfer J, Kaps M. Embolic lesion pattern in stroke patients with patent foramen ovale compared with patients lacking an embolic source. Stroke. 2006;37(8):2159-61. (Pubitemid 44309920)
17. Thaler DE, Ruthazer R, Di Angelantonio E, Di Tullio MR, Donovan JS, Elkind MSV, et al. Neuroimaging findings in cryptogenic stroke patients with and without patent foramen ovale. Stroke. 2013;44(3):675-80.
18. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale. Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation. 2002;105(22):2625-31. (Pubitemid 34596039)
19. Devuyst G, Bogousslavsky J, Ruchat P, Jeanrenaud X, Despland PA, Regli F, et al. Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology. 1996;47(5):1162-6. (Pubitemid 26374880)
20. Homma S, Tullio MRD, Sacco RL, Sciacca RR, Smith C, Mohr JP. Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke. 1997;28(12):2376-81. (Pubitemid 28007635)
21. Schneider B, Bauer R. Is surgical closure of patent foramen ovale the gold standard for treating interatrial shunts? An echocardiographic follow-up study. J Am Soc Echocardiogr. 2005;18(12):1385-91. (Pubitemid 41821186)
22. Wahl A, Jüni P, Mono M-L, Kalesan B, Praz F, Geister L, et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation. 2012;125(6):803-12.
23. Horner S, Niederkorn K, Gattringer T, Furtner M, Topakian R, Lang W, et al. Management of right-to-left shunt in cryptogenic cerebrovascular disease: results from the observational Austrian paradoxical cerebral embolism trial (TACET) registry. J Neurol. 2013;260(1):260-7.
24. • Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke. 2012;43(2):422-31. This is the most recent meta-analysis available and includes data from one randomized trial (CLOSURE 1).
25. Rao S, Sila C. PFO closure for cryptogenic stroke: review of new data and results. Curr Treat Options Cardiovasc Med. 2013;15(3):360-71.
26. • Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991-9. CLOSURE 1 is the first published randomized trial of percutaneous closure versus medical therapy for cryptogenic stroke with PFO.
27. • Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083-91. Report of the PC trial, a randomized trial studying the efficacy of percutaneous closure versus medical therapy for cryptogenic embolism.
28. • Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New Engl J Med. 2013;368(12):1092-100. Report of the RESPECT trial, a randomized trial of percutaneous PFO closure versus medical therapy after cryptogenic stroke.
29. Thaler DE, Wahl A. Critique of closure or medical therapy for cryptogenic stroke with patent foramen ovale. The hole truth? Stroke. 2012;43(11):3147-9.
30. O'Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2009;53(21):2014-8.
31. Opotowsky AR, Landzberg MJ, Kimmel SE, Webb GD. Trends in the use of percutaneous closure of patent foramen ovale and atrial septal defect in adults, 1998-2004. JAMA. 2008;299(5):521-2. (Pubitemid 351214263)
32. Messé SR, Kent DM. Still no closure on the question of PFO closure. N Engl J Med. 2013;368(12):1152-3.
33. Kizer JR. Evaluation of the patient with unexplained stroke. Coron Artery Dis. 2008;19(7):535-40.
34. Doufekias E, Segal AZ, Kizer JR. Cardiogenic and aortogenic brain embolism. J Am Coll Cardiol. 2008;51(11):1049-59. (Pubitemid 351384653)
35. Arboix A, Martí-Vilalta JL. Lacunar stroke. Expert Rev Neurother. 2009;9(2):179-96.
36. Seet RCS, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation. 2011;124(4):477-86.
37. Crovetto F, Ossola MW, Spadaccini G, Duiella SF, Somigliana E, Fedele L. Ischemic stroke recurrence during pregnancy: a case series and a review of the literature. Arch Gynecol Obstet. 2012;286(3):599-604.
38. ClinicalTrials.gov. GORE® HELEX® septal occluder/GORE® septal occluder for patent foramen ovale (PFO) closure in stroke patients - the Gore REDUCE clinical study (HLX 06-03). http://clinicaltrials.gov/ct2/show/ NCT00738894?term=Gore+REDUCE&rank=1 (2008-2013). Accessed 24 Apr 2013.
39. ClinicalTrials.gov. Patent foramen ovale closure or anticoagulants versus antiplatelet therapy to prevent stroke recurrence (CLOSE). http:// clinicaltrials.gov/ct2/show/NCT00562289?term=CLOSE+pfo+trial&rank=1 (2007-2012). Accessed 24 Apr 2013.
40. ClinicalTrials.gov. Device closure versus medical therapy for cryptogenic stroke patients with high-risk patent foramen ovale (DEFENSE-PFO). http://clinicaltrials.gov/ct2/show/NCT01550588?term=DEFENSE-PFO&rank=1 Accessed 24 Apr 2013.
41. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227-76.